Merck Licenses Cyclica’s In-Silico Artificial Intelligence (AI) based Ligand Express Platform

Shots:

• Merck to get rights for Cyclica’s cloud-based in-silico proteome screening AI platform, Ligand Express to screen small molecule for determining polypharmacological profiles
• The focus of agreement is to discover and develop clinical candidates using AI and computational biophysics
• Ligand Express Platform is an AI based platform, used for understanding drug’s effect with captured panoramic view of protein and small molecule in form of on-targets and off-targets

Click here to read full press release/ article | Ref: Merck| Image: Spagnola & Associates